BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29627895)

  • 1. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells.
    Zheng MD; Wang ND; Li XL; Yan J; Tang JH; Zhao XH; Zhang Z
    J Nat Med; 2018 Jun; 72(3):724-733. PubMed ID: 29627895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.
    Yamashita T; Nagano K; Kanasaki S; Maeda Y; Furuya T; Inoue M; Nabeshi H; Yoshikawa T; Yoshioka Y; Itoh N; Abe Y; Kamada H; Tsutsumi Y; Tsunoda S
    Biochem Biophys Res Commun; 2012 Apr; 421(1):140-4. PubMed ID: 22497892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
    Song L; Li Y; Li W; Wu S; Li Z
    J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.
    Ji XM; Ouyang B; Liu H; Liu GW; Wu ZC; Yu HY; Wang CY; Wang ZX; Wang WP
    Chin J Integr Med; 2011 Dec; 17(12):908-16. PubMed ID: 22139542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
    Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
    Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.
    Yang Y; Zhang P; Zhao Y; Yang J; Jiang G; Fan J
    Cancer Biol Ther; 2016 May; 17(5):515-25. PubMed ID: 26492332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin.
    Li X; You M; Liu YJ; Ma L; Jin PP; Zhou R; Zhang ZX; Hua B; Ji XJ; Cheng XY; Yin F; Chen Y; Yin W
    Sci Rep; 2017 Feb; 7():42748. PubMed ID: 28209994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.
    Morimoto A; Serada S; Enomoto T; Kim A; Matsuzaki S; Takahashi T; Ueda Y; Yoshino K; Fujita M; Fujimoto M; Kimura T; Naka T
    Oncotarget; 2014 Sep; 5(17):7776-87. PubMed ID: 25277200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.
    Zagryazhskaya A; Surova O; Akbar NS; Allavena G; Gyuraszova K; Zborovskaya IB; Tchevkina EM; Zhivotovsky B
    Oncotarget; 2015 May; 6(14):12156-73. PubMed ID: 25940438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
    Mattheolabakis G; Ling D; Ahmad G; Amiji M
    Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
    Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
    Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A4 and cancer.
    Wei B; Guo C; Liu S; Sun MZ
    Clin Chim Acta; 2015 Jul; 447():72-8. PubMed ID: 26048190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
    Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
    Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
    Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
    Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549.
    Oh S; Kim Y; Kim J; Kwon D; Lee E
    Biochem Biophys Res Commun; 2010 Aug; 399(1):91-7. PubMed ID: 20643104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
    Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
    Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.